Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
European Heart Journal|August 10, 2014
Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trialWilliam Wijns, Ph Gabriel Steg, Laura Mauri, et al.JACC. Cardiovascular Interventions|April 8, 2017
Detecting Periprocedural Myocardial Infarction in Contemporary Percutaneous Coronary Intervention TrialsErnest Spitzer, Ton de Vries, Rafael Cavalcante, et al.European Journal of Human Genetics : EJHG|February 19, 2004
Polymorphisms in the prion protein gene and in the doppel gene increase susceptibility for Creutzfeldt-Jakob diseaseEsther A Croes, Behrooz Z Alizadeh, Aida M Bertoli-Avella, et al.Journal of the American College of Cardiology|December 6, 2008
Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trialJoost Daemen, Karl Heinz Kuck, Carlos Macaya, et al.JAMA Cardiology|September 27, 2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS TrialMariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, et al.JACC. Cardiovascular Interventions|October 12, 2019
Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary InterventionHector M Garcia-Garcia, Eugène P McFadden, Clemens von Birgelen, et al.JACC. Cardiovascular Interventions|August 24, 2013
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trialPatrick W Serruys, Vasim Farooq, Bindu Kalesan, et al.The Canadian Journal of Cardiology|March 7, 2020
Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERSAna Paula de Faria, Rodrigo Modolo, Ply Chichareon, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 20, 2019
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trialPatrick W Serruys, Mariusz Tomaniak, Ply Chichareon, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 12, 2020
Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trialMariusz Tomaniak, Ply Chichareon, Dominika Klimczak-Tomaniak, et al.Pageof 3